JP Morgan Chase
CLDI icon

JP Morgan Chase’s Calidi Biotherapeutics CLDI Stock Holding History

JP Morgan Chase’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$14 – 7475
2025
Q3 		$14 Buy
9
+4
+80% +$17 ﹤0.01% 7301
2025
Q2 		$14 Buy
+5
New +$24 ﹤0.01% 6969

Other funds holding CLDI

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase's CLDI Position: Q4 2025 in Review

JP Morgan Chase sold out of Calidi Biotherapeutics (CLDI) in Q4 2025, closing a stake of 9 shares — an estimated $14 sold.

JP Morgan Chase first reported a position in CLDI in Q2 2025 and held it in 2 quarters. The position peaked at $14 in Q3 2025. 27 funds tracked by Wall St. Rank hold CLDI as of Q4 2025.

  • JP Morgan Chase reported no remaining Calidi Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 9 Calidi Biotherapeutics shares in Q4 2025, an estimated $14.
  • JP Morgan Chase first reported a position in Calidi Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • JP Morgan Chase's Calidi Biotherapeutics position peaked at $14 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.